Becton, Dickinson and Company (BDX) 股票分析

公司概述

Becton, Dickinson and Company functions as a global developer, manufacturer, and seller of medical supplies, devices, laboratory equipment, and diagnostic products serving healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The firm operates within the Healthcare sector, specifically the Medical Instruments & Supplies industry, positioning itself as a critical provider of essential tools for patient care and medical research. With a market capitalization of $56.32 billion, annual revenue of $21.92 billion, and an employee base of 70,000, the company represents a substantial entity within the biomedical engineering landscape. These valuation and revenue figures indicate that Becton, Dickinson and Company holds a dominant market position, reflecting the high barriers to entry and significant capital requirements inherent in manufacturing specialized medical technology for worldwide distribution.

财务健康

The company reported total revenue of $21.92 billion over the trailing twelve months, generating net income of $1.76 billion and EBITDA of $6.04 billion. The substantial gap between the $21.92 billion revenue and the $1.76 billion net income reveals a cost structure where operating expenses, including cost of goods sold, research and development, and general administrative costs, consume approximately 92% of top-line revenue before arriving at the bottom line. Free cash flow stands at $3.11 billion, which provides the organization with significant financial flexibility to fund capital expenditures, pursue strategic acquisitions, or return capital to shareholders without relying on external financing. The gross margin of 46.8% suggests a pricing power and cost control efficiency typical of high-tech medical device manufacturers, while the operating margin of 13.3% and profit margin of 8.0% indicate the extent of overhead absorption and overall profitability relative to sales. On the balance sheet, the company holds $751.00 million in cash against $19.54 billion in debt, resulting in a debt-to-equity ratio of 77.28, which characterizes a highly leveraged position relative to its equity base. The current ratio of 1.05 indicates that current assets slightly exceed current liabilities, suggesting a tight but manageable short-term liquidity position that requires careful working capital management. Return on equity is 7.0% and return on assets is 4.1%, metrics that reveal the efficiency of management in generating returns on the shareholders' capital and the total asset base, respectively.

估值评估

The trailing twelve-month P/E ratio is 25.36, whereas the forward P/E ratio is 11.51, implying that the market expects earnings to grow significantly in the coming years to justify the current multiple. The price-to-book ratio of 1.75 indicates that the stock trades at a premium of 75% over its book value, reflecting intangible assets, brand strength, and future growth prospects not captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 2.57 and an EV/EBITDA of 10.44 provide context for the stock's price relative to its revenue generation and earnings power, suggesting a valuation that is moderate compared to high-growth biotech peers but premium for a mature medical device firm. The stock's 52-week trading range spans from a low of $127.59 to a high of $187.35, meaning the current price sits within this historical band, having experienced volatility over the past year. The beta value of 0.35 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may serve as a defensive holding during periods of market turbulence.

Growth & Income

Revenue growth year-over-year is 1.6%, while earnings growth year-over-year is 28.6%, indicating that earnings are expanding at a rate substantially faster than revenue, which often implies improved operational leverage, cost efficiencies, or a shift toward higher-margin product mixes. As a dividend payer, the company offers a dividend yield of 2.7% with a payout ratio of 68.1%, a level that is generally sustainable given the robust free cash flow generation and the fact that the payout is well below 100% of earnings. The disparity between the low single-digit revenue growth and the high double-digit earnings growth highlights the company's ability to enhance profitability even in a relatively stagnant top-line environment. Overall, the growth and income profile presents a blend of modest revenue expansion driven by steady demand for medical essentials and strong earnings momentum supported by a healthy dividend yield.